GLPwatch
Papers (10410)
Page 132 of 174, ranked by citation count.
- The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis.
- Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
- Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Patients with Polycystic Ovary Syndrome and Obesity.
- The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.
- Potential roles for eNOS and NrF₂ /HO-1 signaling in the ameliorative effect of lixisenatide on diabetes-induced kidney injury in rats and its amplification by ticagrelor co-administration.
- Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.
- ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide.
- Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
- Older Adults' Views on Insurance Coverage for Weight Management Medications.
- Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.
- Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic.
- Ozempic keeps wowing: trial data show benefits for kidney disease.
- Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin.
- Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
- Liraglutide promotes diabetic corneal epithelial and nerve regeneration by suppressing oxidative stress via the PI3K/AKT signalling pathway.
- Evaluation of A Novel GLP-1R Ligand for PET Imaging of Prostate Cancer.
- Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
- Exenatide administration time-dependently affects the hepatic circadian clock through glucagon-like peptide-1 receptors in the central nervous system.
- The effects of liraglutide on expressions of insulin secretion and beta cell survive associated GPCR genes in pancreatic beta cells.
- Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy.
- Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle.
- Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
- Deciphering the Effects of Semaglutide Across the Glycemic Spectrum.
- The GLP-1 analog, exendin-4, improves bone material properties and strength through a central relay in ovariectomized mice.
- Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.
- Recurrent weight gain after sleeve gastrectomy: conversion to Roux-en-Y gastric bypass versus novel GLP-1 s.
- Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
- Effects of repeated developmental GLP-1R agonist exposure on young adult behavior and hippocampal structure in mice.
- [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?]
- The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
- Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.
- Inclusion of drugs on the World Health Organization's Essential Medicines List: A game-changer for obesity?
- Tirzepatide attenuates estrogen deficiency-induced metabolic dysfunction-associated steatotic liver disease progression by reducing steatosis, inflammation, and fibrosis in obese-diabetic mice.
- Early resuscitation with exendin-4 alleviates acute lung injury after hemorrhagic shock in rats.
- Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats.
- Chronic Stress Alters Hippocampal Renin-Angiotensin-Aldosterone System Component Expression in an Aged Rat Model of Wolfram Syndrome.
- [Incretin therapy and the metabolic syndrome].
- Shedding light on weight loss: A narrative review of medications for treating obesity.
- [Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes].
- Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases.
- Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
- Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
- GLP1R agonists: primary cardiovascular prevention and oral administration.
- Semaglutide may provide sustained weight loss for at least four years, study reports.
- The prospective record-breaking obesity drug tirzepatide raises concerns about affordability.
- Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach.
- Physiology of the Weight Loss Plateau after Calorie Restriction, GLP-1 Receptor Agonism, and Bariatric Surgery.
- Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus.
- Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide.
- Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.
- Liraglutide and systolic blood pressure.
- Convergent Metabolic Pathways in MASH Therapeutics: An AMPK-Centric Analysis.
- Analysis on difference in gastrointestinal hormone levels of patients with the history of diabetes and concurrent nephropathy and study on the role of liraglutide.
- Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.
- The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Lipid Profile of Diabetic Patients Using Statins: A Retrospective Cohort Study in the Diabetic Center of King Salman Bin Abdulaziz Hospital, Saudi Arabia.
- Tirzepatide Lowered Blood Pressure in People With Obesity.
- Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.
- [Incretin therapies and multifactorial clinical approach to cardiometabolic patients].
- Protective roles of liraglutide against brain injury of streptozotocin induced diabetic rats.